Stock listing
Hanover:PSH0 Sernova Biotherapeutics Inc Aktie
German listing (Hanover) of Sernova Biotherapeutics Inc · home listing TSX:SVA
Follow Sernova Biotherapeutics Inc into a list and get an email when it puts out news.
Home listing price · TSX:SVA
$0.09 CAD -0.01 (-10.0%)
Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, TSX:SVA
- Day range
- $0.09 – $0.095 CADNov 20, 2026
- Volume
- 343,510 sharesNov 20, 2026
- Market cap
- $33.99M CADAt the close on Nov 20, 2026 · price × 377.6M shares outstanding
- 52-week range
- $0.09 – $0.20 CADLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $23,311 CADMedian day 75,350 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| TSX:SVA · Home | $0.09 CAD | -0.01 (-10.0%) | 343,510 | $0.09 | $0.095 | $0.09 | $0.10 | Close on Nov 20, 2026 |
| OTC:SEOVF | $0.067 USD | 0.000 (0.0%) | 429 | $0.067 | $0.067 | $0.067 | $0.067 | Close on Nov 20, 2026 |
| Xetra:PSH0 | €0.064 EUR | +0.005 (+8.4%) | 1,196 | €0.059 | €0.068 | €0.059 | €0.059 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · TSX:SVA · CAD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $0.09 | -0.01 | -10.0% | $0.09 | $0.095 | $0.09 | 343,510 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.10 | $0.09 | 300,727 | |
| $0.10 | -0.005 | -4.8% | $0.11 | $0.115 | $0.10 | 303,582 | |
| $0.105 | -0.005 | -4.5% | $0.10 | $0.105 | $0.10 | 111,297 | |
| $0.11 | +0.005 | +4.8% | $0.11 | $0.11 | $0.11 | 6,310 | |
| $0.105 | -0.005 | -4.5% | $0.115 | $0.115 | $0.10 | 102,090 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.115 | $0.11 | 42,611 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.115 | $0.11 | 22,500 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.12 | $0.11 | 58,555 | |
| $0.11 | +0.005 | +4.8% | $0.105 | $0.11 | $0.105 | 32,010 | |
| $0.105 | 0.00 | 0.0% | $0.105 | $0.11 | $0.105 | 12,124 | |
| $0.105 | -0.01 | -8.7% | $0.11 | $0.11 | $0.105 | 98,115 | |
| $0.115 | +0.015 | +15.0% | $0.105 | $0.12 | $0.10 | 149,829 | |
| $0.10 | -0.005 | -4.8% | $0.105 | $0.105 | $0.10 | 39,444 | |
| $0.105 | -0.005 | -4.5% | $0.105 | $0.105 | $0.105 | 47,270 | |
| $0.11 | 0.00 | 0.0% | $0.105 | $0.11 | $0.105 | 26,455 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 2,367 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.105 | 29,778 | |
| $0.11 | 0.00 | 0.0% | $0.105 | $0.11 | $0.105 | 70,630 | |
| $0.11 | 0.00 | 0.0% | $0.115 | $0.115 | $0.11 | 37,444 | |
| $0.11 | -0.01 | -8.3% | $0.12 | $0.12 | $0.11 | 67,500 | |
| $0.12 | +0.01 | +9.1% | $0.11 | $0.12 | $0.11 | 98,400 | |
| $0.11 | -0.01 | -8.3% | $0.12 | $0.12 | $0.11 | 90,000 | |
| $0.12 | 0.00 | 0.0% | $0.12 | $0.12 | $0.12 | 34,900 | |
| $0.12 | 0.00 | 0.0% | $0.12 | $0.12 | $0.12 | 167,000 | |
| $0.12 | 0.00 | 0.0% | $0.11 | $0.12 | $0.11 | 15,800 | |
| $0.12 | +0.01 | +9.1% | $0.12 | $0.12 | $0.11 | 130,200 | |
| $0.11 | -0.01 | -8.3% | $0.11 | $0.12 | $0.11 | 33,800 | |
| $0.12 | 0.00 | 0.0% | $0.12 | $0.12 | $0.12 | 16,400 | |
| $0.12 | 0.00 | 0.0% | $0.12 | $0.12 | $0.11 | 42,600 | |
| $0.12 | 0.00 | 0.0% | $0.12 | $0.12 | $0.12 | 73,700 | |
| $0.12 | +0.01 | +9.1% | $0.11 | $0.12 | $0.11 | 266,900 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.13 | $0.11 | 384,700 | |
| $0.11 | 0.00 | 0.0% | $0.12 | $0.12 | $0.11 | 65,700 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.12 | $0.11 | 37,300 | |
| $0.11 | +0.02 | +22.2% | $0.10 | $0.12 | $0.10 | 1,433,900 | |
| $0.09 | 0.00 | 0.0% | $0.09 | $0.09 | $0.09 | 274,200 | |
| $0.09 | 0.00 | 0.0% | $0.09 | $0.10 | $0.09 | 284,200 | |
| $0.09 | 0.00 | 0.0% | $0.10 | $0.10 | $0.09 | 77,000 | |
| $0.09 | -0.01 | -10.0% | $0.10 | $0.10 | $0.09 | 721,200 | |
| $0.10 | 0.00 | 0.0% | $0.10 | $0.11 | $0.10 | 455,400 | |
| $0.10 | -0.01 | -9.1% | $0.10 | $0.11 | $0.10 | 156,900 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.10 | 264,600 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.10 | 257,400 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 163,800 | |
| $0.11 | +0.01 | +10.0% | $0.11 | $0.11 | $0.10 | 199,000 | |
| $0.10 | -0.01 | -9.1% | $0.11 | $0.12 | $0.10 | 983,200 | |
| $0.11 | -0.03 | -21.4% | $0.14 | $0.14 | $0.11 | 1,227,000 | |
| $0.14 | 0.00 | 0.0% | $0.14 | $0.15 | $0.14 | 547,500 | |
| $0.14 | 0.00 | 0.0% | $0.15 | $0.15 | $0.14 | 500,900 | |
| $0.14 | +0.01 | +7.7% | $0.15 | $0.15 | $0.14 | 350,500 | |
| $0.13 | +0.02 | +18.2% | $0.12 | $0.15 | $0.10 | 1,440,900 | |
| $0.11 | -0.01 | -8.3% | $0.12 | $0.12 | $0.11 | 65,300 | |
| $0.12 | 0.00 | 0.0% | $0.11 | $0.12 | $0.11 | 37,000 | |
| $0.12 | +0.01 | +9.1% | $0.11 | $0.12 | $0.11 | 5,000 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 112,500 | |
| $0.11 | 0.00 | 0.0% | $0.12 | $0.12 | $0.11 | 40,800 | |
| $0.11 | 0.00 | 0.0% | $0.12 | $0.12 | $0.11 | 71,700 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.12 | $0.11 | 51,500 | |
| $0.11 | 0.00 | 0.0% | $0.12 | $0.12 | $0.11 | 4,000 | |
| $0.11 | 0.00 | 0.0% | $0.115 | $0.115 | $0.105 | 68,110 | |
| $0.11 | 0.00 | 0.0% | $0.115 | $0.115 | $0.11 | 40,202 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 121,600 | |
| $0.11 | 0.00 | 0.0% | $0.11 | $0.11 | $0.11 | 44,400 |
Splits
1 split · TSX:SVA · every price before a split is adjusted for it
| Day | Ratio | What |
|---|---|---|
| 1-for-3 | Consolidation |
- Ticker
- Hanover:PSH0
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- Hanover
- Currency
- EUR
What changed lately
Latest news release · Oct 19, 2026
Seraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post Merger BetaNova Biotherapeutics
Latest deck · 2026
Merger or Acquisition (2026)
Merger or acquisition · 16 slides
Latest news
Seraxis and Sernova Announce Appointment of Former FDA Medical Officer Dr. Patricia Beaston as Chief Medical Officer of Seraxis and Post Merger BetaNova Biotherapeutics
Oct 19, 2026
Closed $0.12 (0.0%) on Oct 19, 2026
Sernova and Seraxis Close US$11.2 Million Financing to Fund Merger to Become BetaNova Biotherapeutics and Advance Type 1 Diabetes Cell Therapy Into Near Term Phase 1/2 Clinical Trial
Oct 5, 2026
Closed $0.11 (0.0%) on Oct 5, 2026
Sernova Biotherapeutics to Participate in Noble Capital Markets' Emerging Growth Virtual Equity Conference
Sep 25, 2026
Closed $0.09 (0.0%) on Sep 25, 2026
Sernova Biotherapeutics to Participate in the H.C. Wainwright 28th Annual Global Investor Conference
Sep 10, 2026
Closed $0.14 (0.0%) on Sep 10, 2026
Sernova and Seraxis Enter Definitive Merger Agreement to Create a Differentiated Type 1 Diabetes Islet Cell-Replacement Biotech Company, BetaNova Biotherapeutics
Sep 8, 2026
Closed $0.13 (+18.2%) on Sep 8, 2026
Sernova Biotherapeutics Receives FDA Orphan Drug Designation for Autologous Islet Transplantation for Prevention of Diabetes Due to Total Pancreatectomy
Jun 17, 2026
Closed $0.17 (+21.4%) on Jun 17, 2026
Sernova Biotherapeutics Announces Closing of Recently Approved Financings
Apr 23, 2026
Closed $0.17 (-5.6%) on Apr 24, 2026
Sernova Biotherapeutics Announces Affirmative Voting Results from 2026 Annual General Meeting of Shareholders
Apr 9, 2026
Closed $0.18 (+12.5%) on Apr 9, 2026
Sernova Biotherapeutics Announces Close of Non-Brokered Private Placement Financing
Mar 24, 2026
Closed $0.17 (0.0%) on Mar 24, 2026
2026 Q1 MD&A
Mar 16, 2026
Closed $0.16 (-5.9%) on Mar 16, 2026
Sernova Biotherapeutics Inc on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 18 in the last 12 months · 165 in all · newest Oct 19, 2026 · oldest 2015
- Decks
- 29 decks · latest 2026
Where Sernova Biotherapeutics Inc is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| TSX:SVA · Home listing | TSX | Canada | CAD |
| OTC:SEOVF | OTC | United States | USD |
| Xetra:PSH0 | Xetra | Germany | EUR |
| Tradegate:PSH0 | Tradegate | Germany | EUR |
| gettex:PSH0 | gettex | Germany | EUR |
| Cboe Canada:SVA | Cboe Canada | Canada | CAD |
| LS Exchange:A411DW | LS Exchange | Germany | EUR |
| Lang & Schwarz:A411DW | Lang & Schwarz | Germany | EUR |
| Munich:PSH0 | Munich | Germany | EUR |
| Dusseldorf:PSH0 | Dusseldorf | Germany | EUR |
| Hamburg:PSH0 | Hamburg | Germany | EUR |
| Stuttgart:PSH0 | Stuttgart | Germany | EUR |
| Frankfurt:PSH0 | Frankfurt | Germany | EUR |
| Hanover:PSH0 · This page | Hanover | Germany | EUR |
Valuation
Statements: 4 quarters to Jul 31, 2026 · price Nov 20, 2026
- Enterprise value
- $36.51M CAD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- Negative equity
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- Negative equity
- Beta vs S&P/TSX Composite
- 0.40
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Sernova Biotherapeutics Inc · TSX:SVA | US$23.70M | US$25.46M | n/a | n/a | n/a | n/a | n/a | n/a | 0.40 |
| Original Biomedicals Co Ltd · TPEX:6483 | US$23.81M | US$21.67M | n/a | 1,875× | n/a | 7.1× | n/a | 0.0× | n/a |
| Scynexis, Inc. · NASDAQ:SCYX | US$23.69M | −US$21.66M | n/a | −1.1× | n/a | 0.4× | −53.5% | 0.0× | 1.76 |
| ImmuPharma plc · LSE:IMM | US$23.68M | US$22.77M | n/a | n/a | n/a | 9.9× | n/a | 0.0× | n/a |
| Organoidsciences Ltd. · KRX:476040 | US$23.46M | US$6.52M | n/a | 3.8× | n/a | 1.1× | −814.8% | 0.4× | n/a |
| Immutep Ltd · ASX:IMM | US$23.41M | −US$24.93M | n/a | −2.6× | n/a | 0.6× | −544.8% | 0.0× | n/a |
| ABVC BioPharma, Inc. · NASDAQ:ABVC | US$23.37M | US$25.81M | n/a | n/a | n/a | 1.8× | n/a | 0.2× | 1.39 |
| Incannex Healthcare Inc. · NASDAQ:IXHL | US$23.33M | −US$44.85M | n/a | n/a | n/a | 0.3× | n/a | 0.0× | 0.98 |
| Actinogen Medical Limited · ASX:ACW | US$23.08M | US$15.17M | n/a | n/a | n/a | 1.6× | n/a | 0.2× | n/a |
| BioNxt Solutions Inc · CSE:BNXT | US$22.78M | US$22.72M | n/a | n/a | n/a | n/a | n/a | n/a | 0.22 |
| Polyrizon Ltd. · NASDAQ:PLRZ | US$22.61M | US$7.56M | n/a | n/a | n/a | 0.9× | n/a | 0.0× | 0.67 |
| Median of the others | US$23.39M | US$11.37M | 1.4× | 1.1× | −544.8% | 0.0× | 0.98 |
Forecasts
Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 1.00 CAD · Analysts' mean
- EPS, year to Oct 2026
- -0.025 · 2 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Jonathan Rigby | Chief Executive Officer |
| James Parsons | Chief Financial Officer |
| David Burke | Vice President, Investor Relations |
| Marie Kaldchibachi | Director, Finance |
| Marylyn Rigby | Chief Communications Officer |
| Patricia Beaston | Chief Medical Officer |
Board
| Director | Role |
|---|---|
| John L. Brooks | Chair |
| Bernd Muehlenweg | Director |
| David Paterson | Director |
| Jonathan Rigby | Chief Executive Officer |
| Steven Sangha | Director |
| Tanya Lewis | Director |
Events
- Next results
- Dec 17, 2026 (expected)
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Sep 10, 2026 · After close | 0.0% |
| Q2 2026 | Jun 11, 2026 · After close | −6.3% |
| Q1 2026 | Mar 13, 2026 · After close | −5.9% |
| Q4 2025 | Dec 19, 2025 · After close | +7.7% |
| Q3 2025 | Sep 15, 2025 · After close | 0.0% |
| Q2 2025 | Jun 13, 2025 · After close | −5.9% |
| Q1 2025 | Mar 14, 2025 · After close | +5.6% |
| Q4 2024 | Dec 23, 2024 · After close | 0.0% |
| Q3 2024 | Sep 16, 2024 · After close | 0.0% |
| Q2 2024 | Jun 14, 2024 · After close | −8.8% |
All 19 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | Mar 18, 2024 · After close | −5.0% |
| Q4 2023 | Jan 29, 2024 · Before open | −3.1% |
| Q3 2023 | Sep 12, 2023 · After close | +1.3% |
| Q2 2023 | Jun 13, 2023 · After close | −3.3% |
| Q1 2023 | Mar 16, 2023 · After close | −1.1% |
| Q4 2022 | Jan 27, 2023 | +1.7% |
| Q3 2022 | Sep 14, 2022 · After close | +6.2% |
| Q2 2022 | Jun 27, 2022 · After close | −6.7% |
| Q1 2022 | Feb 13, 2022 · After close | −5.1% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Merger or Acquisition (2026) | Merger or acquisition | 16 slides | 2026 |
| Investor Presentation (February 2025) | Investor deck | 24 slides | February 2025 |
| Investor Presentation (December 2024) | Investor deck | 31 slides | December 2024 |
| Investor Presentation (September 2024) | Investor deck | 21 slides | Sep 12, 2024 |
| Investor Presentation (March 2024) | Investor deck | 32 slides | March 2024 |
| Sernova — Investor Presentation (September 2023) | Investor deck | 27 slides | September 2023 |
| Sernova — Investor Presentation (May 2023) | Investor deck | 21 slides | May 2023 |
| Sernova — Shareholder Meeting (April 2023) | Shareholder meeting | 17 slides | Apr 27, 2023 |
| Technical Presentation (April 2023) | Technical | 10 slides | Apr 24, 2023 |
| Sernova — Investor Presentation (January 2023) | Investor deck | 27 slides | January 2023 |
All 29 decks
Financings
| Raise | Date | In US dollars |
|---|---|---|
| Convertible notes and common stock purchase warrants of Seraxis Closed: US$11.2M raised Buyers: Dr. Steven Sangha / Arlo Investments; Jonathan Rigby; Will Rust Insiders: Insiders participated, including Dr. Steven Sangha / Arlo Investments, Sernova management and Seraxis management Use of proceeds: cGMP manufacturing of SR-02 islet cells and enrollment of T1D patients for the Phase 1/2 clinical trial | Oct 5, 2026 | |
| Unsecured convertible debentures Closed: C$1.5M raised · C$0.15 · Warrants at C$0.25 for 36 months Insiders: Financing made with an insider; insiders participated, treated as related party transactions | Apr 23, 2026 | US$1.1M |
| Private placement of units Closed: C$4M raised Insiders: Unit financing made with an insider; insiders participated, treated as related party transactions Use of proceeds: To retire outstanding loan obligations | Apr 23, 2026 | US$2.92M |
| Private placement of units Update: C$4M · C$0.15 a unit · 1 warrant at C$0.2 for 36 months Insiders: Shareholders approved the issuance of the units to an insider of the Company Use of proceeds: Retire the existing $4.0 million secured term loan maturing April 16, 2026 | Apr 9, 2026 | US$2.93M |
| Private placement of units Announced: C$1.6M · C$0.15 a unit · 1 warrant at C$0.25 for 36 months | Mar 4, 2026 | US$1.17M |
| Private placement of units Tranche closed: C$874,600 raised · C$0.16 a unit · 1 warrant at C$0.4 for 36 months Use of proceeds: General operating capital and launch of final Cohort C in the Phase 1/2 trial of its Cell Pouch Bio-hybrid Organ for type 1 diabetes | Nov 13, 2025 | US$623,912 |
| Unsecured convertible debenture Closed: C$1M raised · Warrants at C$0.2 Buyers: Dr. Steven Sangha (CAD$1,000,000 unsecured convertible debenture and 5,000,000 warrants) Insiders: The debenture and warrants were issued to Dr. Steven Sangha, a shareholder and board member; a related party transaction under MI 61-101 Use of proceeds: Working capital | Mar 5, 2025 | US$695,894 |
Open Financings · Read by 6ix AI from the company's releases
Financials
Annual, in CAD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of revenue | 342.6K | 540.3K | 445.6K | 440.0K | 267.2K | 225.2K | 61.5K | 64.5K | 39.9K | 7.56K |
| Gross profit | -342.6K | -540.3K | -445.6K | -440.0K | -267.2K | -225.2K | -61.5K | -64.5K | -39.9K | -7.56K |
| Research and development | 7.28M | 22.4M | 32.3M | 16.9M | 4.64M | 2.76M | 2.01M | 2.23M | 1.54M | 1.20M |
| Selling, general and administrative | 7.50M | 8.97M | 8.46M | 7.83M | 2.29M | 2.48M | 2.00M | 1.47M | 1.10M | 1.30M |
| Operating income | -15.1M | -31.8M | -41.1M | -24.2M | -6.87M | -5.22M | -3.97M | -3.69M | -2.63M | -2.49M |
| Depreciation and amortization | 342.6K | 540.3K | 445.6K | 440.0K | 267.2K | 225.2K | 61.5K | 64.5K | 39.9K | 7.56K |
| EBITDA | -14.8M | -31.3M | -40.7M | -23.7M | -6.60M | -5.00M | -3.91M | -3.62M | -2.59M | -2.48M |
| Interest expense | 754.8K | 586.9K | 32.1K | 118.0K | 58.4K | 86.3K | 7.27K | 9.71K | 13.8K | 9.69K |
| Income before tax | -15.8M | -32.2M | -39.6M | -24.4M | -6.97M | -5.32M | -3.97M | -3.70M | -2.64M | -2.50M |
| Income tax | -92.2K | 7.00K | -629.0K | 118.0K | 58.4K | 86.3K | 7.27K | 9.71K | 13.8K | 9.69K |
| Net income | -15.7M | -32.2M | -39.0M | -24.5M | -7.02M | -5.41M | -3.98M | -3.70M | -2.64M | -2.50M |
| Earnings per share, basic | -0.05 | -0.10 | -0.13 | -0.09 | -0.03 | -0.03 | -0.02 | -0.02 | -0.02 | -0.02 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 265.0K | 6.01M | 8.72M | 3.78M | 27.9M | 3.95M | 1.80M | 1.74M | 2.63M | 5.20M |
| Short-term investments | 0 | 11.1M | 46.0M | 0 | 0 | 2.01M | 1.00M | 1.00M | 700.0K | |
| Receivables | 122.6K | 298.1K | 1.05M | 1.15M | 448.9K | 506.8K | 735.0K | 471.6K | 641.4K | 231.4K |
| Current assets | 522.6K | 6.47M | 21.0M | 51.1M | 28.3M | 4.61M | 5.32M | 3.32M | 4.31M | 6.20M |
| Property, plant and equipment | 17.7K | 833.9K | 507.4K | 653.7K | 564.7K | 203.4K | 251.5K | 289.0K | 238.5K | 26.6K |
| Goodwill | 316.4K | |||||||||
| Total assets | 764.2K | 7.53M | 22.1M | 52.5M | 29.8M | 5.73M | 5.57M | 3.61M | 4.55M | 6.23M |
| Accounts payable | 17.7M | 17.2M | 6.85M | 3.61M | 379.5K | 529.4K | 472.9K | 182.6K | 182.9K | 116.0K |
| Current liabilities | 24.8M | 20.0M | 9.59M | 4.74M | 1.48M | 878.1K | 686.8K | 341.2K | 901.1K | 846.3K |
| Long-term debt | 1.04M | 0 | 702.6K | |||||||
| Total debt | 4.77M | 569.9K | 136.1K | 276.0K | 393.4K | 734.4K | ||||
| Total liabilities | 25.8M | 20.5M | 9.59M | 4.88M | 1.75M | 1.58M | 686.8K | 341.2K | 901.1K | 846.3K |
| Shareholders' equity | -25.1M | -13.0M | 12.5M | 47.6M | 28.1M | 4.14M | 4.88M | 3.26M | 3.65M | 5.38M |
| Shares outstanding | 328.3M | 307.0M | 303.3M | 273.6M | 245.5M | 197.3M | 175.9M | 159.5M | 158.2M | 148.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -10.9M | -18.9M | -30.3M | -14.4M | -6.84M | -3.94M | -4.19M | -3.92M | -2.74M | -2.55M |
| Capital spending | -3 | -3 | -99.3K | -329.0K | -17.2K | -1.01M | -24.0K | -115.0K | -251.7K | -19.4K |
| Free cash flow | -10.9M | -18.9M | -30.4M | -14.8M | -6.86M | -4.94M | -4.22M | -4.03M | -2.99M | -2.57M |
| Cash from investing | 25.0K | 11.1M | 34.8M | -46.3M | -228.8K | 994.4K | -1.02M | -110.7K | -551.7K | 1.93M |
| Cash from financing | 5.14M | 5.07M | 503.5K | 36.7M | 31.0M | 5.10M | 5.27M | 3.14M | 720.1K | 5.61M |
| Share buybacks | 248.6K | 4.98M | 0 | 36.5M | 29.9M | 3.56M | 4.73M | 2.81M | 470.5K | 255.1K |
| Change in cash | -5.75M | -2.71M | 4.95M | -24.1M | 23.9M | 2.15M | 57.8K | -888.2K | -2.57M | 4.99M |
Cap table
Built by 6ix from Sernova Biotherapeutics Inc’s releases · as of Oct 5, 2026
- Common shares
- 377,642,509
- Fully diluted
- 383,108,759
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 377,642,509 | |
| Warrants | 5,466,250 | Nov 13, 2025 |
Warrants and options
| Lot |
|---|
| Warrants · C$0.25 · expire about Apr 2029 |
| Warrants · C$0.40 · expire about Nov 2028 |
| Warrants · C$0.20 · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 377,642,509 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Bernd Muehlenweg | Director · Since at least Apr 9, 2026 |
| David Burke | Vice President, Investor Relations · Since at least Oct 5, 2026 |
| David Paterson | Director · Since at least Apr 9, 2026 |
| James Parsons | Chief Financial Officer · Since at least Oct 5, 2026 |
| John L. Brooks | Chair · Since at least Sep 23, 2025 |
| Jonathan Rigby | Chief Executive Officer · Since at least Jun 2, 2025 |
| Marie Kaldchibachi | Director, Finance · Since at least Nov 5, 2026 |
| Marylyn Rigby | Chief Communications Officer · Since at least Oct 5, 2026 |
| Patricia Beaston | Chief Medical Officer · Since at least Oct 19, 2026 |
| Steven Sangha | Director · Since at least Oct 5, 2026 |
All 11 people
| Person | Seat |
|---|---|
| Tanya Lewis | Director · Since at least Apr 9, 2026 |
Log in to ask 6ix AI your own questions about Sernova Biotherapeutics Inc.